z-logo
open-access-imgOpen Access
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
Author(s) -
Howard L. Kaufman,
Robert H.I. Andtbacka,
Frances A. Collichio,
Michael Wolf,
Zhongyun Zhao,
Mark Shilkrut,
Igor Puzanov,
Merrick I. Ross
Publication year - 2017
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/x0k6-s254
Subject(s) - oncolytic virus , immunotherapy , clinical trial , cancer immunotherapy , cancer , medicine , oncology , clinical endpoint , virology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom